Agile UX: Designing Together

When you hear the word “agile” is it just a trendy buzzword to you? Do you find it flexible but risky? Too short-sighted and an excuse not to think ahead? Does it conjure up images of sticky notes, cult-like devotion, and taking itself too seriously? 

 

Or are you just bored hearing teams wave the banner of agile as a weapon against “corporateness” only to turn the “process” into the same rigor and rote behavior it claims to be the savior of? (Take a moment to do an eye roll.)

 

You are not alone. If you’re on an agile team or working towards it as a product owner, user experience (UX) practitioner, or developer you probably suspect “we’re doing it wrong.” (Or possible worse, that you’re doing it 100% right.) 

 

And when you add the relatively new discipline of UX to the inherent complex life sciences domain into an agile team — the result can range from chaotic to confusing to frustrating.

 

We can also relate. As we started discussing our experiences working to integrate agile and UX in our life sciences companies — it was remarkable how similar our challenges and evolution was in working towards what “really works in the real world.” 

 

So we’d like to share some of what we learned to help you possibly avoid some of the pitfalls and mistakes we made along the way and provide you with perspective on what “doing it right” means to us and many of our teams.

 

Rethinking the role of agile

It has been said that the first step to recovery is acknowledging there’s a problem, so start by asking yourself this simple question:

 

“Are we getting the most out of the investment in our team’s time working together every two weeks?” 

 

If the answer is anything but “1000% yes… #agile… kumbaya!” there’s room to improve. 

 

For many of our “real world” teams, common challenges that often made the answer “no” included issues like:

 

  • How do we design and develop at the same time and what is the priority of the items we’re working on?
  • Where do we capture and incorporate user, customer, and stakeholder feedback and ideas?
  • How do we get stakeholder buy-in without constant disruption?
    (sorry, refocus 😉 )
  • How do we communicate with the team (often global and distributed) what exactly it is that we’re building?

 

(Re)defining the backlog

The key to overcoming these issues in agile is the backlog. Like the term “agile”, this concept comes with loaded expectations based on people’s roles and experiences. For many agile technical teams, the backlog is simply a list of increments of work for developers defined by a product owner consisting of defined stories that should provide the maximum value to an organization. 

 

So how do UX people, customers, stakeholders, and users fit into this typically narrow definition? Let’s simply expand our definition and how we communicate and use our backlog. The backlog is now:

  • The plan for risk-averse executives 
  • The roadmap for customers / clients / buyers
  • The vision for product marketing / owners
  • Our list of planned experiments for scientists and subject matter experts
  • What to research / ideate / create for UX teams
  • What problems we want to solve for users 
  • What we’re building for development teams

 

To make this change simpler, we recommend dividing the effort into two types of work and two agile tracks: 

  1. Discovery: Ideas and items not fully fleshed out, described, designed, documented, estimated or tested to the level the team feels confident moving them in to development. These raw plans and ideas can come from any of the roles we mentioned above but it is the sole responsibility of the product owner to add and prioritize what work gets done when.
  2. Development: Items the team decides meets their definition of “ready to develop” as they work through Discovery items.  

 

Because agile teams are self organizing the details of how this process exactly works and what specific artifacts are required may vary by team. (Although ideally some consistency helps make it easier for people to work on other teams and teams to coordinate their activity with other teams.)

The type of work we are doing varies in these tracks but the team should not. Any team member can and should be involved in either track where and when appropriate or necessary.

 

Since the development track process is familiar to most people, we’ll focus on how our teams use the Discovery process.

 

Designing in cycles 

Just like in any agile exercise the goal during the Discovery track is to iterate through  increments of work — but instead of releasable software we are producing releasable design artifacts again, that meet the team’s definition of “ready to develop.” That definition often includes standards like estimation, heuristic evaluation and usability testing.

The artifacts can include any set of typical UX deliverables the team agrees provides the “minimal viable documentation” to effectively break down and move into active development.

Staggered discovery and delivery track

For example, one feature needing to be designed may be very straightforward and require a simple sketch or wireframe and a user story to describe where another risky or complex set of functionality may require the team to do research, prototyping, testing or technical research spikes, etc to deliver. 

 

In life sciences, we often find multi-persona user journeys or complex multistep domain-specific processes to be some of the more complex to breakdown, design and describe. We find that in these cases, running the cycles in very short increments and iterating rapidly helps accelerate the design process and build enough of a “backlog of designed stories” for a team to “get ahead” of development. 

 

Many teams will also define what success looks like in the Discovery track — typically to be one to two sprints ahead or in some cases a release or milestone ahead. The goal is to avoid “just-in-time” delivery of Discovery artifacts. 

 

The ideal scenario is that design artifacts for an increment is completed at least one sprint ahead of when they will be implemented in the normal development process. Again, it is up to the team to decide what is “Ready to develop.” 

 

In common UX terms, we practice and operationalize “Design Thinking” through this Discovery process. So using this model, let’s describe how our teams work together in this agile Discovery/ Design track. 

 

Building a shared understanding

Though most of what we are describing can work for any agile software team (some term the concept “dual track agile”) this approach is particularly relevant and aligned to concepts in life sciences. We are “experimenting,” creating and validating our “hypotheses,” running “experiments,” and conducting “peer reviews.” We are working together to Build, Measure, and Learn (from Lean UX) how to solve the market, user, and technical challenges of our project.

 

In short, the goal of this agile Design and Discovery process is to learn together as a team.

Problem and Solutions in Agile

As teams and projects grow, additional roles may expand the group of Discovery contributor like Business analysts, Facilitator / Planner, and UX Researcher, and QA team members. The key question to ask when deciding who should be involved and avoid endless debate and slow progress is: 

 

“What are the artifacts that best will help the team achieve the outcome of the sprint and who will be responsible to produce them?” 

 

For example a QA lead should be involved to produce a persona-driven test plan for workflow testing. Or a UX Researcher may help add insight based on recent interviews or added by the product owner when a particularly risky feature that may require user interviews and testing is being proposed.

 

During the Discovery process, this core group from the team work together through the prioritized list of user stores or ideas identified and prioritized by the product owner using whatever time box is effective. Some teams have workshops and do it all at once, others meet weekly, daily or every few days. Again, it’s agile – so whatever the team decides will be the most productive and yield the best results.

 

Exercises we’ve found to be particularly effective in the discovery process to help the team continue to get better at “designing together”: 

 

 

Here the UX team is critical in facilitating these sessions and helping guide the team in deciding what exercises might be helpful in a given situation. Create experiences that encourage the team to learn how to learn. And remember the goal is to produce “just enough documentation” that the team what it needs to make progress and remove blockers and obstacles to action.

 

Science is about ideas, experimentation and invention

Hopefully the concepts we’ve shared here help you see beyond the agile “hype” and help your teams in life science add experimentation and invention to every sprint.

We’ve found refreshing agile with Discovery / Design sprints gets better ideas from more of the team faster and provides a mechanism to get more real users involved in shaping products and solutions. So go create some great experiences with your agile team!

 

Acknowledgments: We would like to thank our UXLS project members for the healthy discussion and contributions to this article in particular our reviewers Joseph Rossetto and Sven Neumeyer.

Inspirational 2019 UX Conference for the Life Sciences

The User Experience for Life Science team held their 2nd Pistoia Alliance User Experience for Life Sciences Conference on the 8th-9th May 2019 at GSK, Stevenage, UK. It attracted 120 delegates, from over 50 organisations along with some special guests, who gathered for two days of sharing knowledge and hands-on workshops. The conference was designed to foster community collaboration and allow UX practitioners to share best practices in the Life Sciences. In addition to a diversity of talks, a number of hands-on workshops were run alongside the main talks to translate knowledge into practice. This year the conference also had a “new to UX stream” for “non-expert” delegates interested in UX to gain useful insights.

 

Vendor Workshop attendees discussing
Pharma and Vendor workshop delegates discussing key issues.

Conference organisers set out to create a diverse mix of relevant topics over the two days including:

  • Cognitive bias and why it is important
  • Design Ops for the life sciences
  • Design Systems and Teams
  • UX implementation in the life sciences compared to other domains
  • Digital Transformation
  • User testing tips and techniques in the life sciences
  • Various introductory workshops covering UX topics
  • UX considerations for data visualisation
  • Facilitation of UX training in your organisation
  • Design of onboarding experiences

 

The common theme amongst all the presentations were the candidness of the speakers and their passion to help others with similar problems. The breadth and diversity of audience participation also helped to create a community atmosphere of sharing.

 

Pharma and Vendor workshop delegates reviewing proposals brought forth by delegates.

 

During the conference, the UXLS project team, also sought to tackle a common challenge of how to improve the overall user experience of vendor purchased software, especially by Pharma with a panel discussion and also a hands-on workshop. The UXLS project will continue working on this topic using the output generated in this workshop.

 

The feedback received has been overwhelmingly positive and the UXLS project team hope to put on future conferences. 

 

Below are some of the anonymous feedback received:

 

Relevance, variety, quality of talks, venue and facilities left a great overall impression.”

 

“Good balance of talks and workshops for newbies alongside some good theory and method sessions.”

 

“The diversity of experience and passion”

 

The conference would not have been possible without the generous funding from our hosts GSK and sponsors Cognizant, ChemAxon, CCDC and Futureheads.

Sketchnotes by Jenny Cham on UX and Agile

AI in Life Sciences Still Being Held Back by Data Issues and Skills Shortage

Recent Press Release: Boston & London, Wednesday 15 May, 2019

The Pistoia Alliance, a global non-profit that works to lower barriers to innovation in life sciences R&D, today announced new survey results showing access to data (52 percent) and lack of skills (44 percent) are the biggest barriers to the adoption of AI and machine learning (ML). These same issues were also identified by scientists in 2017 – when 24 percent of respondents cited access to data as the biggest challenge to AI adoption, and 30 percent cited lack of skills.  Despite these barriers, use of AI in the life sciences has increased in the past two years, with 70 percent of respondents stating they are using AI, including machine learning and deep learning, in some capacity, up from 44 percent in 2017.

 

“AI has the potential to make a real difference in life sciences, particularly when we look at how data can be used ‘for good’, such as in the drug repurposing datathon we ran with Elsevier earlier this year,” commented Dr Steve Arlington, President of The Pistoia Alliance. “In the life sciences, there is no room for error when it comes to AI, and in order to make the technology work for the industry, we need highly-trained, specialist data experts to meet this challenge. There is now also an abundance of data streams – such as Real World Evidence, clinical trials data, and genomic data, which could have real value in drug discovery and development, as long as we’re able to analyse it. The industry must work closely with academic organisations and educators to highlight these opportunities, and attract the next generation of data scientists.”

 

The survey also highlighted that data quality is another recurring challenge to AI adoption and value; in 2018, 66 percent said data quality was the biggest barrier to using AI in drug design, in 2017, a quarter (26 percent) said it is one of the biggest barriers to all AI projects. Data quality is a problem the life science industry can take immediate steps to address, by ensuring their data complies with the ‘FAIR’ principles; ensuring it is Findable, Accessible, Interoperable and Re-useable. Despite these continuing challenges, less than half (46 percent) of respondents have a team of data scientists in their company dedicated to improving data quality, and only 15 percent said their organisation is planning to build such a team. Given AI adoption in the life sciences looks set to flourish, in order to safeguard patients and reassure regulators, those in the industry must work together to ratify and implement data standards and protocols.

 

“Our research has shown the life science industry is very interested in AI adoption, but that the same issues are still hampering it’s use,” commented Dr Nick Lynch, Strategy Lead for The Pistoia Alliance’s AI Center of Excellence (CoE). “This is why The Pistoia Alliance created our Center of Excellence in AI for Life Sciences. We wanted to provide an opportunity for the industry to work collaboratively on implementing AI successfully, from sharing best practices to collaborating on improving access to quality data – including working to implement standardised data formats that will accelerate adoption. But this won’t happen until we have the life science industry, technology specialists, vendors, and regulators, all in the same ‘room’ and working together to solve the same problems.”

 

The Pistoia Alliance is looking for guidance on the topics it should provide further education and training around, including in its webinar series. Individuals and organisations can provider their suggestions by completing the survey here. This research was conducted via a series of webinars between October 2018 and February 2019 with 190 respondents from the US and Europe.

Join the Center of Excellence for AI in life sciences mailing list here to receive news of events, projects and datathons. For more information on The Pistoia Alliance’s work on AI, please contact Valdimir Makarov.

CoE for AI in Life Sciences – seeks input to future priorities

The Pistoia Alliance is looking at future priorities for our CoE for AI in Life Sciences and Health. Building on the feedback after our recent London workshop Mar 2019 and the webinars & events over the last few months.

Our current list is below and we welcome your views on the priorities here and where you would like to get involved.

 

You can pick your preferences and add new ones by filling in this form

Equally just get in touch with the CoE Project Lead Vladimir Makarov or Nick Lynch

  1. Regulatory landscape for medical devices and pharmaceuticals that rely on AI
  2. Ethics & adoption of AI in Life Sciences & Health
  3. AI/ML Model versioning & the data/model provenance
  4. BioMedical Image processing & Analysis using AI (image feature recognition & quantification)
  5. Flow Cytometry usage
  6. FAIR data, Ontologies & Data Annotation supporting data analysis
  7. Best practices in use of AI in life sciences (e.g. Data quality)
  8. Federated or privacy preserving model building across organisations, secure sharing
  9. Synthetic data for supporting model building in Life Science
  10. Natural Language Processing (NLP) & text extraction
  11. AI in Drug Design (structure optimization, generative drug design/de novo, molecular property prediction, etc)
  12. AI in big data mining
  13. AI supporting Clinical Trials

More new members welcomed in 2018

Since the Q1 2018 the Pistoia Alliance has welcomed the following companies and individuals as new members:

Companies:

Individuals:

  • Melanie Brewer

A complete list of current members can be found here. If you are interested in joining the Pistoia Alliance yourself, all the information you need can be found here.

New members welcomed in Q1 2018

Since the end of 2017 the Pistoia Alliance has welcomed the following companies and individuals as new members:

Companies:

  • Transformative AI
  • Medley Genomics
  • Cubuslab
  • Phenomic AI
  • grit42
  • Discngine
  • MediSapiens
  • Elemental Machines
  • RockStep Solutions

Individuals:

  • Corne Nous
  • Thomas Doerner
  • Chris Morris
  • Gerd Blanke

A complete list of current members can be found here. If you are interested in joining the Pistoia Alliance yourself, all the information you need can be found here.

New members welcomed in Q4 2017

Since mid 2017 the Pistoia Alliance has welcomed the following companies and individuals as new members:

Companies:

  • Congenica
  • Luxoft
  • Bioraft
  • Cyclica
  • Abbvie
  • Arxspan
  • EPAM
  • Vivenics
  • Healthcare Improvement Foundation
  • The HDF Group

Individuals:

  • Jeremy Frey
  • Till Dettmering
  • Francisco Fernandez

A complete list of current members can be found here. If you are interested in joining the Pistoia Alliance yourself, all the information you need can be found here.

New members welcomed in Q4 2017

Since mid 2017 the Pistoia Alliance has welcomed the following companies and individuals as new members:

Companies:

  • Congenica
  • Luxoft
  • Bioraft
  • Cyclica
  • Abbvie
  • Arxspan
  • EPAM
  • Vivenics
  • Healthcare Improvement Foundation
  • The HDF Group

Individuals:

  • Jeremy Frey
  • Till Dettmering
  • Francisco Fernandez

A complete list of current members can be found here. If you are interested in joining the Pistoia Alliance yourself, all the information you need can be found here.

The Pistoia Alliance and Scilligence Announce HELM Web Editor

Boston, January 30, 2017 – The Pistoia Alliance and Scilligence Corporation are pleased to announce the release of the HELM Web Editor which brings HELM’s industry standard biomolecular representation to the browser, greatly enhancing the deployability of the technology for its adopters

As the therapeutic utilization of complex and unique biomolecules has become commonplace in drug discovery R&D, scientists have struggled to represent these entities in their information systems, forcing them to use various “pick and mix” approaches that include multiple nomenclatures and textual descriptions. HELM, the open biomolecular representation standard, has solved this problem by providing a means to represent various types of complex macromolecules (e.g. nucleotides, proteins, antibodies and antibody-drug conjugates) including those that contain non-natural elements such as chemically modified amino acids.

The Pistoia Alliance formalized the HELM notation, originally created by Pfizer scientists as an open standard in early 2013, and publicly released the related software toolkit and editor to the Open Source community. Since its release, HELM has benefited from a growing ecosystem of global adopters and contributors including organizations such as Bristol Myers Squibb, Pfizer, Novartis, Roche, GSK, Ionis, Merck and Co, Scilligence, NextMove Software, ACD/Labs, Arxspan, BioChemfusion, Dassault Systèmes BIOVIA, ChemAxon, Perkin-Elmer, quattro research, EMBL-EBI, NCBI (PubChem) and RDKit.

While the original HELM Applet editor, supporting HELM Notation 1.0 and developed using Java, made it easier for scientists to draw and view macromolecules, technology evolved, leaving the applet unsupported by many browsers. The new HELM Web Editor is completely built on JavaScript, which removes dependencies and increases the compatibilities with modern browsers.

2017 will see further updates to the web editor to add monomer and ruleset management, support for the HELM 2.0 ambiguity features and antibody editing.

As major contributors to this project, Novartis AG and Ionis Pharmaceuticals are adopting the new HELM Web Editor.

Dr. Eric Swayze, Vice President of Chemistry and Neuroscience Drug Discovery at Ionis Pharmaceuticals adds: “The new HELM Web Editor makes it easier for our scientists to adopt the HELM technologies, which helps them to more efficiently represent and register complex chemically modified biomolecules, which facilitates exchange of information within the team.”

Dr. Jinbo Lee, CSO of Scilligence adds: “We appreciate the opportunity working on the project. The new HELM Web Editor’s zero-footprint and enhanced usability will help the scientific community including life-science, academic and technology organizations adopt the HELM standard.”

About Pistoia Alliance

The Pistoia Alliance is a global, not-for-profit members’ organization made up of life science companies, technology and service providers, publishers, and academic groups working to lower barriers to innovation in life science and healthcare R&D. It was conceived in 2007 and incorporated in 2009 by representatives of AstraZeneca, GSK, Novartis and Pfizer who met at a conference in Pistoia, Italy. Its projects transform R&D through pre-competitive collaboration. It overcomes common R&D obstacles by identifying the root causes, developing standards and best practices, sharing pre-competitive data and knowledge, and implementing technology pilots. There are currently over 80 member companies; members collaborate on projects that generate significant value for the worldwide life sciences R&D community, using the Pistoia Alliance’s proven framework for open innovation.

About Scilligence

Scilligence is a leading innovator of web-based cheminformatics and bioinformatics solutions designed for any device, browser, and platform. Scilligence’s tools enhance the knowledge sharing and productivity of researchers in discovery and development of small molecule and biologic therapeutics.

Contact

Krystyana Roman, Marketing Specialist, Scilligence. kroman@scilligence.com, +1 (617) 520-4588

Claire Bellamy, Project Manager, Pistoia Alliance. claire.bellamy@pistoiaalliance.org, +44 7823 470513

 

The Pistoia Alliance Calls for Greater Collaboration on Wearable Devices in R&D

Removing silos and pooling expertise will change medical research and benefit more patients

Boston, 2nd November, 2016The Pistoia Alliance, a global, not-for-profit alliance that works to lower barriers to innovation in life sciences R&D, is calling on the pharmaceutical industry to support greater collaboration around wearable device initiatives. This theme echoed at The Pistoia Alliance’s annual member conference in Boston earlier this month. Sohini Chowdhury, senior vice president of research partnerships at The Michael J Fox Foundation  (MJFF), the world’s largest non-profit funder of Parkinson’s research, discussed the need for increased cooperation between all links in the life sciences research chain to realise the potential of technology in R&D.

“From patients to physicians, from scientists to trial sponsors – everyone wants more data,” commented Ms Chowdhury. “Wearable devices will be a crucial ‘self-reported’ source of that data, but we know there is still a hill to climb toward field-wide integration. Now, we’re trying to close the loop, and explore the value of wearables for the entire ecosystem. By pooling our resources, we can build consensus and make these reams of data accessible – which will advance our understanding of disease and testing of new therapies.”

During her keynote, Ms Chowdhury also spoke about MJFF’s early wearable device projects. One project includes a wearable sensor in a smartwatch, which transmits data via a smartphone to the cloud. This enables researchers to monitor patients’ movements 24/7, collecting 150 data points per second (over 4 million data points per person per day). With such a large amount of data collected, one of the biggest challenges is in analysing that data. Data scientists need the input of clinical experts to direct their analyses, and scientists and researchers need the help of computational experts to ‘crunch’ the numbers. This kind of collaborative effort will become fundamental to unearthing insights from wearable device data and is a core aim of The Pistoia Alliance.

“The Pistoia Alliance applauds the excellent work that MJFF has been doing, to encourage collaborative efforts that will accelerate research in the field of Parkinson’s. When we take a cross-industry view we can see, however, that many pharmaceutical companies are developing their own wearable devices and applications, in all therapeutic areas – without common industry standards to govern quality and interoperability,” commented Dr Steve Arlington, President of The Pistoia Alliance. “The result is that considerable amounts of time and money are wasted developing unique solutions that cannot interact, and with no facility to share the data gathered. This fragmented approach benefits neither patients nor payers in the slightest. The lack of communication, whether it be between countries or companies, is a significant barrier to the development of new therapies. The Pistoia Alliance was formed to overcome these barriers to innovation, and to offer a unique platform to foster collaboration.”

The Pistoia Alliance creates initiatives to avoid the waste of time and resources resulting from siloed research programmes. Its projects bring together key constituents to identify root causes of R&D inefficiencies; it has also created a proven legal framework for open innovation. One of the Pistoia Alliance’s key successes is its role as a founding partner in not-for-profit foundation, The tranSMART Foundation, an open source platform where interoperable data can be accessed and merged with external proprietary datasets from other parties.

“The tranSMART Foundation was incubated by The Pistoia Alliance, and formed as a result of collaborative effort between scientists all over the world,” commented Keith Elliston, CEO of The tranSMART Foundation. “New data-types – such as that from wearable devices or Internet of Things sensors – are growing in volume all the time. Making sense of all of these data requires a collective endeavour and a platform which improves accessibility. At tranSMART, we are able to provide this environment to support organizations such as the MJFF to achieve its mission.”

For more information about The Pistoia Alliance, please visit: pistoiaalliance.org

For more information about The Michael J Fox Foundation, please visit: michaeljfox.org

For more information about The tranSMART Foundation, please visit: transmartfoundation.org

–ENDS—

About The Pistoia Alliance:

The Pistoia Alliance is a global, not-for-profit members’ organization made up of life science companies, technology and service providers, publishers, and academic groups working to lower barriers to innovation in life science and healthcare R&D. It was conceived in 2007 and incorporated in 2009 by representatives of AstraZeneca, GSK, Novartis and Pfizer who met at a conference in Pistoia, Italy. Its projects transform R&D through pre-competitive collaboration. It overcomes common R&D obstacles by identifying the root causes, developing standards and best practices, sharing pre-competitive data and knowledge, and implementing technology pilots. There are currently over 80 member companies; members collaborate on projects that generate significant value for the worldwide life sciences R&D community, using the Pistoia Alliance’s proven framework for open innovation.

About The Michael J. Fox Foundation for Parkinson’s Research
As the world’s largest nonprofit funder of Parkinson’s research, The Michael J. Fox Foundation is dedicated to accelerating a cure for Parkinson’s disease and improved therapies for those living with the condition today. The Foundation pursues its goals through an aggressively funded, highly targeted research program coupled with active global engagement of scientists, Parkinson’s patients, business leaders, clinical trial participants, donors and volunteers. In addition to funding more than $650 million in research to date, the Foundation has fundamentally altered the trajectory of progress toward a cure. Operating at the hub of worldwide Parkinson’s research, the Foundation forges groundbreaking collaborations with industry leaders, academic scientists and government research funders; increases the flow of participants into Parkinson’s disease clinical trials with its online tool, Fox Trial Finder; promotes Parkinson’s awareness through high-profile advocacy, events and outreach; and coordinates the grassroots involvement of thousands of Team Fox members around the world. For more information, visit us at michaeljfox.org, on Facebook or Twitter.

About The tranSMART Foundation

The tranSMART Foundation is a non-profit organization that provides an open-source, cloud-based, data-sharing and analysis platform that enables scientists at universities, disease foundations, pharmaceutical companies, and government agencies around the world to share pre-competitive data in a way that saves money and time in translating research findings into new therapies and diagnostic tools.  Current Gold Members of the Foundation include: Pfizer, Roche, Sanofi, Takeda, and the University of Michigan.  Founded to steward the tranSMART platform, the Foundation is headquartered in Wakefield, Massachusetts with Centers of Excellence in Ann Arbor, Mich.; London, England; Boston, Mass.; and Amsterdam, Netherlands. The tranSMART Foundation can also be found on the web at www.tranSMARTFoundation.org.

Media Contacts:

Carmen Nitsche, Pistoia Alliance
+001 510-589-3355 / carmen.nitsche@pistoiaalliance.org

Michelle Allison, Spark Communications
+44 207 436 0420 / michelle@sparkcomms.co.uk

Counting on the Pistoia Alliance: A strategy for Growth

Land was the raw material of the agricultural age.

Iron was the raw material of the industrial age.

Data is the raw material of the information age.

Alec Ross, Columbia University

Please also refer to the list of questions and answers related to this strategy update.

Introduction

The world of life sciences R&D is changing rapidly. To ensure the Pistoia Alliance continues to remain relevant, it needs to change with it. While the Pistoia Alliance has been successful in the past, with a strong and growing membership, alongside a series of successful projects, which have improved the efficiency of global life sciences R&D, the Pistoia Alliance faces a number of challenges which must be met in order to ensure its continued relevance.

The Pistoia Alliance has had an impact on life sciences R&D through pre-competitive collaboration. However, it has not been as significant or as wide ranging as hoped. Furthermore, there are some indications its impact may be diminishing. To ensure that the Pistoia Alliance is able to continue to contribute and to influence global R&D strategy at the highest levels, a new strategy is required.

There is a need to restructure the membership of the Pistoia Alliance itself. While we have many excellent members who are unstinting in their contributions, we need to be represented at higher levels in our member organisations if we are to achieve our objectives, and influence life sciences R&D at the strategic level. At the same time, we need to guard against losing our strengths in operational knowledge and skills. The Pistoia Alliance needs to review its membership categories and its governance to ensure we are attractive to the broader health and life sciences communities.

Alongside the change in our membership, we need to review the projects we support. While we have had significant success with a number of these, we have as yet significantly to influence the top levels of life sciences R&D. This new strategy will see the Pistoia Alliance adopt a new approach, becoming involved with new and emerging areas of technology, and influencing the sector on a more strategic level.

We will focus on technologies which support science, technology and digital healthcare at the strategic level. This will see an increase in activities in areas underpinned by e.g. “Omics”, Big Data, Wearables, Robotics and the Internet of Things (IoT).

The Pistoia Alliance has always helped support innovative start-up companies through our many projects. With the growing importance of these companies, increasing our level of support for them will prove beneficial to the Pistoia Alliance. As such, we will be extending the President’s Start-Up Challenge, encouraging more companies to enter, increasing the value of the prizes, and through these efforts increasing our involvement with key stakeholders such as venture capitalists.

Furthermore, we aim to attract the interest of industry investment groups, become one of the most important and well known industry reference point for any start-up looking for validation, and offer high-level, industry support through our members and mentors. This will allow us to utilise the start-up community in helping improve life sciences R&D globally.

All of this will bring about significant change for the Pistoia Alliance, and with that change, a number of risks. However, failure to adapt to these challenges will result in the Pistoia Alliance disappearing, and with it, the many benefits we provide.

While the finances of the Pistoia Alliance have been and continue to be tightly managed, if we do not adopt these changes and increase our revenues, we will run out of money in less than eighteen months.

The life science industry is undergoing massive change across all areas at the moment, making the role of organisations such as the Pistoia Alliance more important than ever. Life sciences R&D would benefit from improved efficiencies and through areas such as pre-competitive collaboration, the Pistoia Alliance can be a powerful force in advocating this and we will look to partner with others to make this happen. Failure to grasp this opportunity will find the Pistoia Alliance declining in relevance.

This new strategy will provide the opportunity for the Pistoia Alliance to enjoy a long and effective future, ensuring we are able to achieve our goal of supporting life sciences R&D globally.

Building a Global Membership

Currently, the Pistoia Alliance has a strong and growing membership across many areas of life sciences and across all levels. However, we need to be represented at higher levels in organisations if we are to achieve our objectives, and influence life sciences R&D at the strategic level.

Since the formation of the Pistoia Alliance, our members have worked tirelessly to support our goals. While this has resulted in a number of successful projects which have improved R&D in life sciences, it has not resulted in the Pistoia Alliance making a large impact.

In order for the Pistoia Alliance to influence the very top levels of life sciences R&D we must broaden our membership. To do this, we must build a reputation within the industry. We must ensure that our projects are seen as being relevant, and providing value. While we have excellent representation at certain levels of the life sciences industry, particularly in the areas of domain expertise and skills, we need to be influencing strategy at the very highest levels and building an industry-leading reputation.

In parallel we need to change the composition of our membership. While pharmaceutical companies may be the single most important part of the network, we need to include others from related and highly influential areas such as regulatory agencies, healthcare providers, service providers and innovators.

To support these changes and to ensure the continued relevance of the Pistoia Alliance, we need radically to restructure how we charge. Membership fees will need to be increased across the organisation or we will run the risk of not having the funds to support our activities.

We will also simplify the current membership structure, removing the existing categories, and charging members according to their size. The current membership division between pharmaceutical/biotech and technical/vendors will also be removed.

The increased funds will enable the Pistoia Alliance to undertake ever more significant projects, which will have a greater impact on global life sciences R&D.

The extension of our membership base will ensure that the Pistoia Alliance is positioned not only to influence life sciences R&D, but also actively to lead in the development of innovative new approaches to tackling the many challenges faced by the sector as a whole.

Supporting Life Sciences R&D Globally

Currently, the life sciences sector is undergoing significant change as it faces a number of challenges. Underpinning many of these challenges are issues around R&D. As many of the so-called ‘easy’ targets have been identified and treatments developed, the industry now needs to focus on more complex and difficult targets. Associated with this is an increased cost in R&D as more complex and expensive methods are required for effective drug discovery. While the objective of the Pistoia Alliance is not to help companies identify novel drug targets or compounds, it is to help with the increasing costs of R&D by reducing the barriers to innovation.

Through pre-competitive collaboration, the Pistoia Alliance can support its members as they strive to improve their R&D. We have had some significant success through our previous projects, such as SESL (Semantically Enriched Scientific Literature) which spawned the IMI Open PHACTs project, Sequence Services which has given rise to several start-up companies, the Vocabulary Standards Initiative which in turn laid foundations for the Ontology Mapping project, HELM (the Hierarchical Editing Language for Macromolecules) which is enjoying increasing adoption globally, and CSCS (Controlled Substance Compliance Services) which is now seen as a useful and successful innovation in the compound management domain.

However, past success is no indication of future success and we must adapt our approach to an ever-changing world. A significant change will be the creation of a budget to support specific projects as agreed by a new sub-committee of the Pistoia Alliance Board called the Portfolio Investment Committee. This will enable the organisation to move quickly to develop new projects as required. This will not replace the traditional funding model with members contributing to projects as they see fit, but will give the Pistoia Alliance the flexibility to exploit rapidly developing opportunities.

We will continue to support our many projects currently underway, which include the Ontology Mapping Service and the Chemical Safety Library, but as ever, we rely on our members to help us identify and develop new projects for the benefit of the sector.

One significant change to our strategy will be in the provision of more active support and for greater engagement with start-up companies. Start-up companies are becoming central to innovation in life sciences, often developing the most innovative technologies and approaches to tackling global problems.

The inaugural President’s Start-Up Challenge has proved successful with a large number of excellent entries from innovative start-up companies, and we want to build on that. The Pistoia Alliance will become one of the significant organisations in fostering innovative start-up companies.

We will use the Start-Up Challenge as the basis for a sustained programme which will see the Pistoia Alliance build strong relationships with life sciences venture capitalists, and their supporting organisations. Through this, and a programme to identify and support the most innovative start-ups, the Pistoia Alliance will become the place for these companies to receive external validation and become the most important and well known industry reference point for any start up looking for validation, and providing high-level industry support. Having successfully launched the inaugural Start-Up Challenge last year, we had an excellent response from the global life sciences R&D community. With the Challenge now established, we need to build on this, increasing awareness in not only the investor and start-up community, but also among large established companies.

The Pistoia Alliance has built a track record in identifying and developing new technologies and techniques, and by combining this with our growing number of start-up members, we can improve life sciences R&D.  By building links with the investment community, we will be able to support our many members and position the Pistoia Alliance as an expert in identifying and fostering innovation.

RFI published: HELM Web-based Editor

The HELM (Hierarchical Editing Language for Macromolecules) 2.0 project has today published an RFI requesting estimates for the creation of a web-based editor.

In addition to the transition from one architecture to another, this work will include:

  1. Adding the ability to define areas of ambiguity in molecules in accordance with the HELM2 specification.
  2. Adding the Helm Antibody Editor (HAbE) functionality so there is a single editor package.
  3. Expanding the range of small molecule editors that can be integrated by implementing a structure drawing API.
  4. Removing the dependency on yFiles.

The RFP documentation is in five parts, and is available in this folder:

The individual files may be downloaded as PDF files via the links below:

  1. Pistoia Alliance HELM Web-based Editor RFI V1_0
  2. HELM Web-based Editor Requirements Specification V1_0.pdf
  3. Ambiguous HELM Line Notation Design.doc
  4. HELM Web-based Editor Conceptual Wireframes.pdf
  5. HELM Monomer Editor Conceptual Wireframes.pdf

Confirmation of intent to participate should be received by Claire Bellamy at claire.bellamy@pistoiaalliance.org by 10am GMT on Monday 25th January.